Tredaptive: Additional Phase III data

Additional data from the investigator-led, double-blind, placebo-controlled, European and Chinese Phase III HPS2-THRIVE trial in 25,673 patients at high risk for cardiovascular events showed that the primary composite endpoint of coronary death, non-fatal MI, stroke or revascularization occurred in 13.2% of patients receiving Tredaptive plus statin therapy vs. 13.7% of patients receiving statin therapy alone at a median follow-up of 3.9 years (p=0.29). Tredaptive plus statin therapy also significantly increased the incidence of diabetic complications, new-onset diabetes, skin rashes, infections, bleeding and gastrointestinal problems vs. statin therapy alone. The trial was conducted by researchers at Oxford University and funded by Merck. Data were presented at the American College of Cardiology meeting in San Francisco. ...